MedTrace Logo

Trastuzumab Rezetecan and Adebrelimab as Neoadjuvant Therapy for HER2-Positive Muscle-Invasive Bladder Cancer

NCT07624201 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 58

Last updated 2026-06-03

No results posted yet for this study

Summary

This study aims to evaluate the efficacy and safety of neoadjuvant trastuzumab rezetecan combined with adebrelimab for the treatment of HER2-positive muscle-invasive bladder cancer.

Conditions

  • Muscle-Invasive Bladder Cancer (MIBC)

Interventions

DRUG

Trastuzumab Rezetecan Combined with Adebelizumab

Trastuzumab Rezetecan 3.2 mg/kg, Q3W, in combination with Adebrelimab 1200 mg, Q3W, for a total of 3 cycles. Subjects will undergo preoperative imaging and surgical eligibility assessment at 3-4 weeks after the last dose of neoadjuvant therapy. Those who meet the surgical criteria will receive either transurethral resection or radical resection.

Sponsors & Collaborators

  • The Fourth Affiliated Hospital of China Medical University

    collaborator OTHER

  • Jilin Provincial Tumor Hospital

    collaborator OTHER

  • Tianjin Medical University Second Hospital

    collaborator OTHER

  • First Hospital of China Medical University

    collaborator OTHER

  • Harbin Medical University

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-01
Primary Completion
2028-06-01
Completion
2029-06-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07624201 on ClinicalTrials.gov